Navigation Links
Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
Date:6/2/2008

ated for treatment of bypass stenosis, aneurysms and for emergency situations such as perforations.

About ITGI Medical

ITGI medical is engaged with research and development, manufacturing and marketing of heterologous tissue covered stents. Over and Under(R) is the first among series of heterologous covered stents designed to treat coronary lesions and aneurysms.

Contact:

Danna Moran

Director of Marketing

ITGI Medical Ltd.

P: + 972-72-2200335

dannam@itgimedical.com


'/>"/>
SOURCE ITGI Medical LTD
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
2. National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications
3. National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti-Aging Applications
4. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
5. Preclinical Research on Coronary Stent with CeloNova BioSciences Polyzene(R)- F Nanocoating Receives Award at CIRSE 2007
6. ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients
7. PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents
8. Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System
9. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
10. Tryton Medical Receives CE Mark Approval for its Side-Branch Stent
11. Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... chronic pain, announced the results of its annual general ... a transformational year in Relmada,s history and it set ... said Sergio Traversa , chief executive officer of ... key financial, human resource and clinical development objectives that ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
(Date:12/17/2014)... Diego, CA (PRWEB) December 17, 2014 ... and activation agency and member of the Huntsworth Health ... Gonzales to its executive team. In her role, Gonzales ... , “We are incredibly honored to welcome a ... Agency Chief and CEO, Gaëtan Fraikin. “She is a ...
(Date:12/17/2014)... LEXINGTON, Mass. , Dec. 17, 2014   ... a biopharmaceutical company developing therapeutic products for rare disorders, ... Healthcare Conference being held in San Francisco, ... , President and Chief Executive Officer, will present on ... p.m. EST).  The presentation will be webcast live and ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
... - Epizyme, Inc., a company leading the discovery and ... today announced the publication of breakthrough new research in ... (USA). The discovery, centered on the epigenetic ... of basic science into targeted therapies for the safe ...
... it took his computer to boot up, Klui began to ... store enormous quantities of data, but they are slow; every ... information is transferred from the hard disk into RAM (random ... and energy consumption runs into the hundreds of millions of ...
... 15, 2010 Celladon Corp., a biopharmaceutical company ... treatments for cardiovascular diseases, today announced that 12-month ... of MYDICAR® demonstrated significant improvements in clinical outcomes ... patients treated with the genetically-targeted enzyme replacement therapy. ...
Cached Biology Technology:Epizyme identifies novel opportunity for treatment of genetically defined human B-cell lymphomas 2Racetrack memory 2Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo 2Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo 3Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo 4
(Date:12/17/2014)... 16, 2014 Research and Markets ... the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend ... for medical sensors in biomedical applications. Chemical sensors ... and correct diagnosis during surgical procedures. The Global ...
(Date:12/11/2014)... WINSTON SALEM, N.C. , Dec. 10, 2014  That ... known for quite a while. Hypertension – the medical term ... disease in the early 1800s, and the inflatable cuff that,s ... That doesn,t, however, mean there,s nothing new about hypertension, ... punctured some long-held beliefs about the condition and the best ...
(Date:12/10/2014)... SAN DIEGO , Dec. 9, 2014 ... and collaboration catalyst that provides the connective tissue that ... by enabling them to easily share client-level information; earned ... Foundation to expand to organizations serving seniors aging in ... San Diego" partner on December 11 th 4-6p. ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... created by researchers at the San Diego Supercomputer Center ... scientists to study evolutionary relationships among large populations of ... having to understand how to operate large, complex computer ... CIPRES (Cyberinfrastructure for Phylogenetic RESearch) Gateway, is ...
... The Cystic Fibrosis Foundation has awarded a Marshall University ... Dr. Hongwei Yu, professor in the Department of Biochemistry ... of Medicine, will help further his lab,s work to ... in the lungs of cystic fibrosis (CF) patients. ...
... policies governing the storage and use of surplus blood samples ... process range from explicit to non-existent, leaving many parents ill-informed ... according to a team led by a member of the ... from the University of Utah. A report on their analysis ...
Cached Biology News:SDSC's CIPRES Gateway provides window to the past -- and fast 2SDSC's CIPRES Gateway provides window to the past -- and fast 3Cystic Fibrosis Foundation funds Marshall research 2Most states unclear about storage, use of babies' blood samples, new study finds 2Most states unclear about storage, use of babies' blood samples, new study finds 3Most states unclear about storage, use of babies' blood samples, new study finds 4
...
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient...
... GeneBLAzer cell-based assays utilize the ... of the negatively charged fluorescent beta-lactamase ... esters readily enter the cell, where ... converts them into their negatively charged ...
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient vir...
Biology Products: